Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 6/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460163 | 0.91 | FLT3 (0.58) | CFTRFLT3MAPTPTGER4THRB | |
| SCHEMBL5459377 | 0.89 | CFTR (0.60) | CFTRFLT3MAPTPTGER4MEN1 | |
| SCHEMBL5458963 | 0.87 | FLT3 (0.71) | FLT3MAPTTHRBRXFP1MGAM | |
| SCHEMBL5459985 | 0.87 | CFTR (0.57) | CFTRFLT3MAPTPTGER4MEN1 | |
| SCHEMBL5453424 | 0.86 | CFTR (0.59) | CFTRFLT3MAPTTHRBMEN1 | |
| SCHEMBL5455744 | 0.83 | FLT3 (0.56) | FLT3MAPTTHRBRXFP1MGAM | |
| SCHEMBL5459795 | 0.83 | KMT2A (0.59) | CFTRFLT3MEN1KMT2ACNR2 | |
| SCHEMBL5456065 | 0.82 | CFTR (0.56) | CFTRFLT3MAPTRXFP1MEN1 | |
| SCHEMBL5445080 | 0.80 | CFTR (0.54) | CFTRFLT3MAPTTHRBRXFP1 | |
| SCHEMBL5452113 | 0.80 | FLT3 (0.55) | CFTRFLT3MAPTTHRBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | claimed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | CFTR 2030/4885FLT3 3509/4885MAPT 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.